Exhibit 99.1 Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights ● Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on- track for the second half of 2024. ● Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% of all lung cancer cases occur in never-smokers with NSCLC; Harmonic™ continues patient enrollment in the US. ● Phase 1 clinical ...